



ICOTYDE™
(icotrokinra) tablets

IT'S UNBELIEVABLE

The first and only IL-23R targeted oral peptide in a once-daily pill^{1,2}

Pill not actual size.

ONE PILL, ONCE A DAY¹

Wake + Take

Upon waking, take with water on an empty stomach
at least 30 minutes before eating

No loading dose or
titration required

No messy,
time-consuming application

No refrigeration
or preparation

Warnings and Precautions include infections, tuberculosis, and immunizations.¹

IL-23R, interleukin-23 receptor.

INDICATION

ICOTYDE™ (icotrokinra) 200 mg is indicated for the treatment of moderate to severe plaque psoriasis in adults and pediatric patients 12 years of age and older who weigh at least 40 kg who are candidates for systemic therapy or phototherapy.

IMPORTANT SAFETY INFORMATION

WARNINGS AND PRECAUTIONS

Infections

Avoid treatment with ICOTYDE in patients with any

Please see Important Safety Information throughout. Please read the full [Prescribing Information](#) and [Medication Guide](#) for ICOTYDE.

Provide the [Medication Guide](#) to your patients and encourage discussion.

Infections (cont'd)

clinically important active infection until the infection resolves or is adequately treated. In patients with a chronic infection or a history of recurrent infection, consider the risks and benefits prior to prescribing ICOTYDE. Instruct patients to seek medical advice if signs or symptoms of clinically important infection occur. If a patient develops such an infection and/or is not responding to standard therapy, monitor the patient closely and discontinue ICOTYDE until the infection resolves.



ICOTYDE™
(icotrokinra) tablets

PRESCRIBE ICOTYDE 200 mg¹

Scan to see more reasons to believe in ICOTYDE as your first-choice systemic therapy.¹

IcotydeHCP.com



Data rates may apply.



Pill not actual size.

MORE ON ICOTYDE 200 mg ADMINISTRATION¹:

For patients who have difficulty swallowing tablets, ICOTYDE can be dispersed in water. Swallow ICOTYDE whole. Do not crush, split, or chew pills. If a patient misses a dose, instruct them to take the missed dose as soon as possible and return to the normal dosing schedule the following day.

See full Prescribing Information for full dosing instructions.

References: 1. ICOTYDE [Prescribing Information]. Horsham, PA: Janssen Biotech, Inc. 2. Fourie AM, Cheng X, Chang L, et al. JNJ-77242113, a highly potent, selective peptide targeting the IL-23 receptor, provides robust IL-23 pathway inhibition upon oral dosing in rats and humans. *Sci Rep.* 2024;14(1):17515. doi:10.1038/s41598-024-67371-5

IMPORTANT SAFETY INFORMATION (cont'd)

WARNINGS AND PRECAUTIONS (cont'd)

Tuberculosis (TB)

Consider evaluating for TB prior to initiating treatment with ICOTYDE based on clinical judgement. Consider anti-TB therapy prior to initiating ICOTYDE in patients with a past history of latent or active TB in whom an adequate course of treatment cannot be confirmed. Monitor patients for signs and symptoms of active TB during and after ICOTYDE treatment. Avoid administering ICOTYDE to patients with active TB.

Immunizations

Avoid use of live vaccines in patients during treatment with ICOTYDE. Medications that interact with the immune system may increase the risk of the infection following administration of live vaccines. Prior to initiating therapy with ICOTYDE, complete immunizations according to current immunization guidelines.

ADVERSE REACTIONS

Most common adverse reactions ($\geq 1\%$) are headache, nausea, cough, fungal infection, and fatigue. The adverse reactions observed in pediatric patients were

consistent with the most common adverse reactions ($\geq 1\%$) observed in the overall population.

USE IN SPECIFIC POPULATIONS

Moderate or Severe Renal Impairment

Monitor for potential adverse reactions when ICOTYDE is used in patients with an estimated glomerular filtration rate (eGFR) < 60 mL/min.

Pregnancy

The available data on the use of ICOTYDE during pregnancy are insufficient to evaluate for a drug-associated risk of major birth defects, miscarriage, or other adverse maternal or fetal outcomes.

Please read the full [Prescribing Information](#) and [Medication Guide](#) for ICOTYDE.

Provide the [Medication Guide](#) to your patients and encourage discussion.

cp-564098v1

Johnson & Johnson

© Johnson & Johnson and its affiliates 2026 03/26 cp-560026v1

 **ICOTYDE**TM
(icotrokinra) tablets